Department of Radiology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
J Neurol. 2023 May;270(5):2649-2658. doi: 10.1007/s00415-023-11594-5. Epub 2023 Mar 1.
Studies of glymphatic dysfunction in Parkinson's disease (PD) patients have attracted much attention in recent years. However, the relationships between glymphatic dysfunction and clinical symptoms remains unclear.
To determine whether the diffusion tensor image analysis along the perivascular space (DTI-ALPS) affect the severity and types of motor and non-motor symptoms in PD patients.
De novo PD patients and controls who performed both DTI and I-DaTscan single photon emission computed tomography (SPECT) scanning were retrieved from the international multicenter Parkinson's Progression Marker Initiative (PPMI) cohort. Glymphatic system was evaluated by the DTI-ALPS. Motor symptoms were assessed by Movement Disorders Society Unified Parkinson's Disease Rating Scale III (MDS-UPDRS-III). The influence of glymphatic activity on motor and non-motor symptoms was explored by multivariate linear regression models.
A total of 153 PD patients (mean age 60.97 ± 9.47 years; 99 male) and 67 normal controls (mean age 60.10 ± 10.562 years; 43 male) were included. The DTI-ALPS index of PD patients was significantly lower than normal controls (Z = - 2.160, p = 0.031). MDS-UPDRS III score (r = - 0.213, p = 0.008) and subscore for rigidity (r = - 0.177, p = 0.029) were negatively correlated with DTI-ALPS index. The DTI-ALPS index was significantly associated with MDS-UPDRS-III score (β = - 0.160, p = 0.048) and subscore for rigidity (β = - 0.170, p = 0.041) after adjusting for putamen dopamine transporter availability and clinical factors.
Our results showed distinct relationships between glymphatic dysfunction and the severity and types of PD motor symptoms, suggesting the potential of DTI-ALPS index as a biomarker for PD motor symptoms.
近年来,对帕金森病(PD)患者的糖液功能障碍的研究引起了广泛关注。然而,糖液功能障碍与临床症状之间的关系尚不清楚。
确定弥散张量成像沿血管周围空间(DTI-ALPS)分析是否影响 PD 患者的运动和非运动症状的严重程度和类型。
从国际多中心帕金森病进展标志物倡议(PPMI)队列中检索到新诊断的 PD 患者和同时进行 DTI 和 I-DaTscan 单光子发射计算机断层扫描(SPECT)扫描的对照组。通过 DTI-ALPS 评估糖液系统。通过运动障碍学会统一帕金森病评定量表 III(MDS-UPDRS-III)评估运动症状。通过多元线性回归模型探讨糖液活性对运动和非运动症状的影响。
共纳入 153 例 PD 患者(平均年龄 60.97±9.47 岁;99 名男性)和 67 名正常对照(平均年龄 60.10±10.562 岁;43 名男性)。PD 患者的 DTI-ALPS 指数明显低于正常对照组(Z=-2.160,p=0.031)。MDS-UPDRS III 评分(r=-0.213,p=0.008)和僵硬亚评分(r=-0.177,p=0.029)与 DTI-ALPS 指数呈负相关。DTI-ALPS 指数与 MDS-UPDRS-III 评分(β=-0.160,p=0.048)和僵硬亚评分(β=-0.170,p=0.041)显著相关,在调整纹状体多巴胺转运体可用性和临床因素后。
我们的研究结果表明,糖液功能障碍与 PD 运动症状的严重程度和类型之间存在明显的关系,提示 DTI-ALPS 指数作为 PD 运动症状生物标志物的潜力。